Zymeworks Inc

Discover how Zymeworks Inc. is advancing cancer treatment with multifunctional biotherapeutics—boosting investor confidence, driving innovation, and shaping precision medicine.

Discover how Zymeworks’ CFO Kristin Stafford’s new stock options and restricted‑stock grants reshape executive ownership and signal strategic shifts in its cancer‑biotherapeutic pipeline.

New CFO and FDA Fast‑Track approval signal Zymeworks’ push toward commercial success with ADC ZW191 for platinum‑resistant ovarian cancer.

Discover how Zymeworks Inc. is redefining antibody‑drug conjugates at AACR—explore its novel RAS‑inhibitor platform, promising Phase‑I data, and market impact.

Discover how Zymeworks’ innovative multifunctional biotherapeutics could reshape cancer treatment and drive investor confidence despite its clinical‑stage status.

Zymeworks Inc. has halted the development of its cancer drug ZW171, leading to a decline in its stock price and sparking concerns about the company’s future pipeline and revenue streams.

Zymeworks Inc., a clinical-stage biotech company, navigates market fluctuations and challenges in the biotech sector while remaining committed to innovation and partnerships in its mission to develop multifunctional biotherapeutics for cancer treatm…

Zymeworks Inc is expanding its pipeline despite modest revenue growth, but its financials paint a mixed picture, contrasting with BeiGene’s strong sales and profitability.